AMINO DITHIOPERACID THIOESTER COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF

Abstract

An amino dithioperacid thioester compound, a preparation method therefor, and use thereof. The structural formula of compound is as shown in formula I: wherein m=1-11, X is a nitrogen-containing aliphatic heterocyclic ring, and a nitrogen atom in the aliphatic heterocyclic ring is connected to a carbon atom of a thiocarbonyl group. The compounds disclosed by the invention are found to be capable of relieving muscular atrophy and lipolysis caused by cancer cachexia through in-vivo and in-vitro experiments. The compounds are also capable of obviously relieving weight and food intake reduction caused by cancer cachexia in animal experiments, so that the carbamo(dithioperoxo)thioates compounds have the effect on resisting cancer cachexia, can be applied to the treatment of cancer cachexia and related diseases, and become one kind of ideal cancer cachexia treatment medicament.

##STR00001##

Claims

1. A carbamo(dithioperoxo)thioate compound of formula I: ##STR00030## or its pharmaceutically acceptable salt thereof, wherein, m=1-11, preferably, m=1-9; X is a nitrogen-containing aliphatic heterocycle and the nitrogen atom in the aliphatic heterocycle is connected to the carbon atom of the thiocarbonyl group.

2. The carbamo(dithioperoxo)thioate compound or its pharmaceutically acceptable salt according with claim 1, wherein, m=3-5, preferably, m=5.

3. The carbamo(dithioperoxo)thioate compound or its pharmaceutically acceptable salt according with claim 1, wherein the aliphatic heterocycle may contain oxygen atom.

4. The carbamo(dithioperoxo)thioate compound or its pharmaceutically acceptable salt according with claim 1, wherein the nitrogen-containing aliphatic heterocycle is selected from saturated monocyclic aliphatic heterocycle, fused or spiro derivative of saturated monocyclic aliphatic heterocycle.

5. The carbamo(dithioperoxo)thioate compound or its pharmaceutically acceptable salt according with claim 4, wherein the saturated nitrogen-containing monocyclic aliphatic heterocycle is 4-7 membered heterocycle; preferably, saturated nitrogen-containing monocyclic aliphatic heterocycle is 4-6 membered heterocycle.

6. The carbamo(dithioperoxo)thioate compound or its pharmaceutically acceptable salt according with claim 4, wherein the saturated nitrogen-containing monocyclic aliphatic heterocycle is selected from pyrrolidine, substituted pyrrolidine, piperidine, morpholine, azetidine, piperazine; preferably, the saturated nitrogen-containing monocyclic aliphatic heterocycle is pyrrolidine.

7. The carbamo(dithioperoxo)thioate compound or its pharmaceutically acceptable salt according with claim 4, wherein the ring which connected with a saturated nitrogen-containing monocyclic aliphatic heterocycle to form a fused-ring heterocycle or spirocycle contains four to six atoms.

8. The carbamo(dithioperoxo)thioate compound or its pharmaceutically acceptable salt according with claim 7, wherein the ring which connected to the saturated nitrogen-containing monocyclic aliphatic heterocycle to form a fused-ring heterocycle or spirocycle is selected from any one of the following: ##STR00031##

9. The carbamo(dithioperoxo)thioate compound or its pharmaceutically acceptable salt according with claim 1, wherein the nitrogen-containing aliphatic heterocycle may contain a substituent group. The substituent group is preferably hydroxy group or C1-4 alkyl group.

10. The carbamo(dithioperoxo)thioate compound or its pharmaceutically acceptable salt according with claim 1, wherein the nitrogen-containing aliphatic heterocycle is selected from pyrrolidine, substituted pyrrolidine, piperidine, morpholine, azetidine, piperazine, indoline, isoindolin, octahydro-1H-indole, octahydro-1H-isoindole, 2-oxa-6-azaspiro[3.4]octane.

11. The carbamo(dithioperoxo)thioate compound or its pharmaceutically acceptable salt according with claim 1, wherein the nitrogen-containing aliphatic heterocycle is selected from pyrrolidine, octahydro-1H-isoindole, azetidine, 2-oxa-6-azaspiro[3.4]octane; preferably, nitrogen-containing aliphatic heterocycle is pyrrolidine.

12. The carbamo(dithioperoxo)thioate compound or its pharmaceutically acceptable salt according with claim 1, wherein said compound is selected from the following compounds or the derivatives of the following compounds in which the nitrogen-containing aliphatic heterocyclic ring may contain substituent group: ##STR00032## ##STR00033##

13. A pharmaceutical composition, characterized in that, comprising the carbamo(dithioperoxo)thioate compound or its pharmaceutically acceptable salt according with claim 1, and its pharmaceutically acceptable additive, preferably, the additive comprises pharmaceutically acceptable carrier, diluent agent or excipient.

14. The carbamo(dithioperoxo)thioate compound or its pharmaceutically acceptable salt according with claim 1 in the preparation of an anti-cachexia drug, especially an anti-cancer cachexia drug application.

15. The pharmaceutical composition according to claim 13, in the preparation of an anti-cachexia drug, especially an anti-cancer cachexia drug application.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0066] FIG. 1 shows the HE staining images of the control group in Example 18.

[0067] FIG. 2 shows the HE staining images of the model group in Example 18.

[0068] FIG. 3 shows the HE staining images of experimental group 1 in Example 18.

[0069] FIG. 4 shows the HE staining images of experimental group 2 in Example 18.

[0070] FIG. 5 shows the HE staining images of experimental group 3 in Example 18.

[0071] FIG. 6 shows the HE staining images of experimental group 4 in Example 18.

[0072] FIG. 7 shows the HE staining images of experimental group 5 in Example 18.

[0073] FIG. 8 shows the HE staining images of experimental group 6 in Example 18.

[0074] FIG. 9 shows the IE staining images of experimental group 7 in Example 18.

[0075] FIG. 10 shows the HE staining images of experimental group 8 in Example 18.

[0076] FIG. 11 shows the HE staining images of experimental group 9 in Example 18.

[0077] FIG. 12 shows the HE staining images of experimental group 10 in Example 18.

[0078] FIG. 13 shows the HE staining images of experimental group 11 in Example 18.

[0079] FIG. 14 shows the HE staining images of experimental group 12 in Example 18.

[0080] FIG. 15 shows the HE staining images of experimental group 13 in Example 18.

[0081] FIG. 16 shows the HE staining images of experimental group 14 in Example 18.

[0082] FIG. 17 shows the HE staining images of experimental group 15 in Example 18.

[0083] FIG. 18 shows the HE staining images of experimental group 16 in Example 18.

[0084] FIG. 19 shows the HE staining images of experimental group 17 in Example 18.

[0085] FIG. 20 shows the HE staining images of experimental group 18 in Example 18.

[0086] FIG. 21 shows the HE staining images of experimental group 19 in Example 18.

[0087] FIG. 22 shows the HE staining images of experimental group 20 in Example 18.

[0088] FIG. 23 shows the HE staining images of experimental group 21 in Example 18.

[0089] FIG. 24 shows the HE staining images of experimental group 22 in Example 18.

[0090] FIG. 25 shows the HE staining images of experimental group 23 in Example 18.

[0091] FIG. 26 shows the HE staining images of experimental group 24 in Example 18.

[0092] FIG. 27 shows the HE staining images of experimental group 25 in Example 18.

[0093] FIG. 28 shows the HE staining images of experimental group 26 in Example 18.

[0094] FIG. 29 shows the HE staining images of experimental group 27 in Example 18.

[0095] FIG. 30 shows the HE staining images of experimental group 28 in Example 18.

[0096] FIG. 31 shows the HE staining images of experimental group 29 in Example 18.

[0097] FIG. 32 shows the HE staining images of experimental group 30 in Example 18.

[0098] FIG. 33 shows the HE staining images of experimental group 31 in Example 18.

[0099] FIG. 34 shows the HE staining images of experimental group 32 in Example 18.

[0100] FIG. 35 shows the HE staining images of experimental group 33 in Example 18.

[0101] FIG. 36 shows the HE staining images of experimental group 34 in Example 18.

[0102] FIG. 37 shows the HE staining images of experimental group 35 in Example 18.

[0103] FIG. 38 shows the HE staining images of experimental group 36 in Example 18.

[0104] FIG. 39 shows the HE staining images of experimental group 37 in Example 18.

[0105] FIG. 40 shows the HE staining images of experimental group 38 in Example 18.

[0106] FIG. 41 shows the HE staining images of experimental group 39 in Example 18.

[0107] FIG. 42 shows the HE staining images of experimental group 40 in Example 18.

[0108] FIG. 43 shows the HE staining images of experimental group 41 in Example 18.

[0109] FIG. 44 shows the HE staining images of experimental group 42 in Example 18.

[0110] FIG. 45 shows the HE staining images of experimental group 43 in Example 18.

[0111] FIG. 46 shows the HE staining images of experimental group 44 in Example 18.

[0112] FIG. 47 shows the graph of the glycerol content test results of the experimental samples in Example 19.

[0113] FIG. 48 shows the change curve of body weight of the tumor-bearing mice in Example 20.

[0114] FIG. 49 shows the change curve of body weight of the tumor-free mice in Example 20.

[0115] FIG. 50 is the tumor volume change curve of the mice in Example 20.

[0116] FIG. 51 shows the real photograph of tumors of the mice in Example 20.

[0117] FIG. 52 shows the change curve of the average daily food intake of the mice in Example 20.

[0118] FIG. 53 shows the change curve of the average accumulative food intake of the mice in Example 20.

[0119] FIG. 54 shows the graph of the gastrocnemius muscle mass measurement results of mice in Example 20.

[0120] FIG. 55 shows the real photograph of the gastrocnemius muscle of the mice in Example 20.

[0121] FIG. 56 shows the graph of grasping force test results of the mice's muscle in Example 20.

[0122] FIG. 57 shows the graph of the epididymal fat mass measurement results in mice in Example 20.

[0123] FIG. 58 shows the real photograph of the epididymal fat of mice in Example 20.

DETAILED METHODS AND EXAMPLES

[0124] In order to improve the drawbacks and defects of existing technology, the present invention relates to a series of carbamo(dithioperoxo)thioate compound, its preparation and application in the treatment of cachexia, especially cancer cachexia and related diseases.

[0125] The present invention provides novel carbamo(dithioperoxo)thioate compounds with good anti-cachexia activity, especially carbamo(dithioperoxo)thioate compounds with nitrogen-containing aliphatic heterocyclic ring as shown in the formula (I):

##STR00009##

[0126] Wherein,

[0127] m=1-11, preferably, m=1-9.

[0128] X is a nitrogen-containing aliphatic heterocyclic ring and the nitrogen atom in the aliphatic heterocyclic ring is connected to the carbon atom of the thiocarbonyl group.

[0129] Preferably, X is selected from four-membered nitrogen-containing aliphatic heterocyclic ring and its fused-ring heterocyclic derivatives or spirocyclic derivatives, five-membered nitrogen-containing aliphatic heterocyclic ring and its fused-ring heterocyclic derivatives or spirocyclic derivatives, six-membered nitrogen-containing aliphatic heterocyclic ring and its fused-ring heterocyclic derivatives or spirocyclic derivatives,

[0130] Further preferably, X is selected from pyrrolidine, substituted pyrrolidine, piperidine, morpholine, azetidine, piperazine, indoline, isoindolin, octahydro-1H-indole, octahydro-1H-isoindole, 2-oxa-6-azaspiro[3.4]octane.

[0131] The present invention relates to following compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17:

##STR00010## ##STR00011##

[0132] The present invention also relates to the application of carbamo(dithioperoxo)thioate compounds in the treatment of cachexia, especially cancer cachexia and related diseases.

[0133] The present invention also aims to provide the method to prepare carbamo(dithioperoxo)thioate compounds, especially the preparation of carbamo(dithioperoxo) thioate compounds with nitrogen-containing aliphatic heterocyclic ring.

[0134] Taking compound 1 for example, the method of preparing the compounds in the present invention is shown as following:

##STR00012##

[0135] The method of pharmacology experiment adopted in the present invention is well known to technician in this research field.

[0136] In the present invention, the C2C12 cells (mouse myoblasts), 3T3-L1 cells (mouse adipocytes) and C26 cells (mouse colon cancer cells), used in the present invention, were obtained from the cell bank of the Type Culture Collection, Chinese Academy of Sciences. BALB/c mice were obtained from Shanghai Lingchang Biotechnology Co., Ltd.

[0137] In the present invention, petroleum ether (boiling point 60-90° C.), purchased from Sinopharm Chemical Reagent Co., Ltd.

[0138] FBS (fetal bovine serum), purchased from Biological Industries Co., Ltd.

[0139] Horse serum, purchased from Gibco Co., Ltd.

[0140] High glucose DMEM medium, purchased from Hyclone Co., Ltd.

[0141] RPMI-1640 medium, purchased from Hyclone Co., Ltd.

[0142] Phenol red-free high glucose DMEM medium, purchased from Hyclone Co., Ltd.

[0143] P/S antibiotics (penicillin-streptomycin) was purchased from Hyclone Co., Ltd.

[0144] Dexamethasone, purchased from Sigma-Aldrich Co., Ltd.

[0145] IBMX (3-isobutyl-1-methylxanthine) broad-spectrum phosphodiesterase inhibitor, purchased from Sigma-Aldrich Co., Ltd.

[0146] Human recombinant insulin was purchased from Shanghai Jinmai Bio. Co., Ltd.

[0147] Glycerol detection kit was purchased from Beijing Prilai Gene Technology Co., Ltd.

[0148] High glucose DMEM medium containing 10% FBS (the composition is 10% FBS+1% P/S+89% high glucose DMEM medium).

[0149] RPMI 1640 medium containing 10% FBS (the composition is: 10% FBS+1% P/S+89% RPMI-1640 medium). 2% HS differentiation medium (the composition is: 2% HS+1% P/S+97% high glucose DMEM medium).

[0150] The information of instruments used in the following examples are listed as:

[0151] Instruments used in chemical synthesis:

[0152] Rotary Evaporator: Buchi, Rotavapor R-200:

[0153] Column chromatography: Silica gel (200-300 mesh) and thin-layer chromatography plates were purchased from Sinopharm Chemical Reagent Co., Ltd.

[0154] Instruments used in the structure characterization and analysis:

[0155] Fluorescence microscope: Olympus, IX-73. .sup.1H NMR, .sup.13C NMR: Varian Model Mercury 400 MHz.

[0156] The preparation and application of carbamo(dithioperoxo)thioate compound in the present invention is further exemplified as following.

Example 1: Synthesis of Compound 1

[0157] ##STR00013##

[0158] Pyrrolidine (58 μL, 0.70 mmol) and octane-1-thiol (122 μL, 0.70 mmol) were added in anhydrous dichloromethane (10 mL), the reaction mixture was cooled in an ice bath. Carbon disulfide (43 μL, 0.70 mmol) was then added dropwise, followed by slow addition of triethylamine (108 μL, 0.77 mmol). After a further five minutes, a solution of CBr.sub.4 (466 mg, 1.41 mmol) in dichloromethane was added, followed by stirring at room temperature for two hours. The solution was washed with water (3×10 mL), saturated NaCl solution (2×10 mL) and dried over sodium sulfate. The product was further purified by column chromatography (DCM:PE=1:1) to yield the white solid (121 mg, 59.3%). .sup.1H NMR (400 MHz, Chloroform-d): δ 3.97 (t, J=7.0 Hz, 2H), 3.75 (t, J=6.9 Hz, 2H), 2.86 (t, J=7.4 Hz, 2H), 2.12 (p, J=6.9 Hz, 2H), 2.00 (p, J=6.9 Hz, 2H), 1.67 (p, J=7.4 Hz, 2H), 1.39 (p, J=6.9 Hz, 2H), 1.27 (q, J=5.9, 5.3 Hz, 8H), 0.88 (t, J=6.6 Hz, 3H).

Example 2: Synthesis of Compound 2

[0159] ##STR00014##

[0160] Pyrrolidine (58 μL, 0.70 mmol) and decane-1-thiol (146 μL, 0.70 mmol) were added in anhydrous dichloromethane (10 mL), the reaction mixture was cooled in an ice bath. Carbon disulfide (43 μL, 0.70 mmol) was then added dropwise, followed by slow addition of triethylamine (108 μL, 0.77 mmol). After a further five minutes, a solution of CBr.sub.4 (466 mg, 1.41 mmol) in dichloromethane was added, followed by stirring at room temperature for two hours. The solution was washed with water (3×10 mL), saturated NaCl solution (2×10 mL) and dried over sodium sulfate. The product was further purified by column chromatography (DCM:PE=1:1) to yield the white solid (139 mg, 62.1%). .sup.1H NMR (400 MHz, Chloroform-d): δ 3.97 (t, J=7.0 Hz, 2H), 3.75 (t, J=6.9 Hz, 2H), 2.86 (t, J=7.4 Hz, 2H), 2.12 (p, J=6.8 Hz, 2H), 2.00 (p, J=6.9 Hz, 2H), 1.68 (q, J=7.3 Hz, 2H), 1.39 (p, J=6.9 Hz, 2H), 1.27 (d, J=5.8 Hz, 12H), 0.88 (t, J=6.7 Hz, 3H). .sup.13C NMR (150 MHz, Chloroform-d): δ 193.02, 56.64, 50.53, 38.69, 31.89, 29.54, 29.49, 29.31, 29.21, 28.63, 28.58, 26.51, 24.20, 22.68, 14.12.

Example 3: Synthesis of Compound 3

[0161] ##STR00015##

[0162] Pyrrolidine (83 mg, 1.17 mmol) and undecane-1-thiol (219 mg, 1.17 mmol) were added in anhydrous dichloromethane (10 mL), the reaction mixture was cooled in an ice bath. Carbon disulfide (71 μL, 1.17 mmol) was then added dropwise, followed by slow addition of triethylamine (178 μL, 1.29 mmol). After a further five minutes, a solution of CBr.sub.4 (776 mg, 2.34 mmol) in dichloromethane was added, followed by stirring at room temperature for two hours. The solution was washed with water (3×10 mL), saturated NaCl solution (2×10 mL) and dried over sodium sulfate. The product was further purified by column chromatography (EA:PE=1:25) to yield the white solid (230 mg, 59%). .sup.1H NMR (400 MHz, Chloroform-d) δ 3.68 (t, J=6.1 Hz, 2H), 3.39 (t, J=6.0 Hz, 2H), 3.03 (t, J=7.2 Hz, 2H), 1.90-1.77 (m, 2H), 1.77-1.65 (m, 2H), 1.51-1.37 (m, 2H), 1.16 (s, 2H), 1.00 (s, 14H), 0.62 (t, J=5.5 Hz, 3H). .sup.13C NMR (151 MHz, Chloroform-d) δ 192.86, 54.20, 49.92, 35.98, 31.28, 28.97, 28.88, 28.70, 28.59, 28.36, 28.23, 25.40, 23.66, 22.05, 13.48.

Example 4: Synthesis of Compound 4

[0163] ##STR00016##

[0164] Pyrrolidine (58 μL, 0.70 mmol) and dodecane-1-thiol (168 μL, 0.70 mmol) were added in anhydrous dichloromethane (10 mL), the reaction mixture was cooled in an ice bath. Carbon disulfide (43 μL, 0.70 mmol) was then added dropwise, followed by slow addition of triethylamine (108 μL, 0.77 mmol). After a further five minutes, a solution of CBr.sub.4 (466 mg, 1.41 mmol) in dichloromethane was added, followed by stirring at room temperature for two hours. The solution was washed with water (3×10 mL), saturated NaCl solution (2×10 mL) and dried over sodium sulfate. The product was further purified by column chromatography (DCM:PE=1:1) to yield the white solid (141 mg, 58%). .sup.1H NMR (400 MHz, Chloroform-d): δ 3.97 (t, J=7.0 Hz, 2H), 3.75 (t, J=6.8 Hz, 2H), 2.86 (t, J=7.4 Hz, 2H), 2.12 (p, J=6.8 Hz, 2H), 2.00 (p, J=6.6 Hz, 2H), 1.66 (p, J=7.2 Hz, 2H), 1.38 (d, J=7.8 Hz, 2H), 1.25 (s, 16H), 0.88 (t, J=6.6 Hz, 3H). .sup.13C NMR (150 MHz, Chloroform-d): δ 193.07, 56.63, 50.52, 38.73, 31.92, 29.64, 29.59, 29.50, 29.35, 29.22, 28.65, 28.59, 26.51, 24.20, 22.69, 14.12.

Example 5: Synthesis of Compound 5

[0165] ##STR00017##

[0166] Pyrrolidine (83 mg, 1.17 mmol) and tridecane-1-thiol (250 mg, 1.16 mmol) were added in anhydrous dichloromethane (10 mL), the reaction mixture was cooled in an ice bath. Carbon disulfide (71 μL, 1.17 mmol) was then added dropwise, followed by slow addition of triethylamine (178 μL, 1.29 mmol). After a further five minutes, a solution of CBr.sub.4 (776 mg, 2.34 mmol) in dichloromethane was added, followed by stirring at room temperature for two hours. The solution was washed with water (3×10 mL), saturated NaCl solution (2×10 mL) and dried over sodium sulfate. The product was further purified by column chromatography (EA:PE=1:25) to yield the white solid (100 mg, 27%). .sup.1H NMR (400 MHz, Chloroform-d) δ 3.91 (t, J=6.8 Hz, 2H), 3.62 (t, J=6.8 Hz, 2H), 3.26 (t, J=7.4 Hz, 2H), 2.11-2.00 (m, 2H), 1.96 (dd, J=13.5, 6.7 Hz, 2H), 1.66 (dd, J=14.7, 7.2 Hz, 2H), 1.40 (dd, J=14.8, 8.5 Hz, 2H), 1.24 (s, 18H), 0.85 (t, J=6.3 Hz, 3H). .sup.13C NMR (151 MHz, Chloroform-d) δ 192.71, 54.35, 49.92, 36.15, 31.29, 29.04, 29.02, 28.97, 28.88, 28.72, 28.59, 28.37, 28.23, 25.40, 23.67, 22.06, 13.48.

Example 6: Synthesis of Compound 6

[0167] ##STR00018##

[0168] Pyrrolidine (58 μL, 0.70 mmol) and tetradecane-1-thiol (191 μL, 0.70 mmol) were added in anhydrous dichloromethane (10 mL), the reaction mixture was cooled in an ice bath. Carbon disulfide (43 μL, 0.70 mmol) was then added dropwise, followed by slow addition of triethylamine (108 μL, 0.77 mmol). After a further five minutes, a solution of CBr.sub.4 (466 mg, 1.41 mmol) in dichloromethane was added, followed by stirring at room temperature for two hours. The solution was washed with water (3×10 mL), saturated NaCl solution (2×10 mL) and dried over sodium sulfate. The product was further purified by column chromatography (EA:PE=1:1) to yield the white solid (140 mg, 53.1%). .sup.1H NMR (400 MHz, Chloroform-d): δ 3.97 (t, J=7.0 Hz, 2H), 3.75 (t, J=6.9 Hz, 2H), 2.86 (t, J=7.4 Hz, 2H), 2.12 (p, J=6.9 Hz, 2H), 2.00 (p, J=6.9 Hz, 2H), 1.68 (q, J=7.4 Hz, 2H), 1.46-1.34 (m, 2H), 1.26 (s, 20H), 0.93-0.83 (m, 3H). .sup.13C NMR (150 MHz, Chloroform-d): δ 192.99, 56.63, 50.53, 38.69, 31.93, 29.69, 29.65, 29.58, 29.49, 29.36, 29.21, 28.64, 28.57, 26.51, 24.20, 22.69, 14.13.

Example 7: Synthesis of Compound 7

[0169] ##STR00019##

[0170] Pyrrolidine (58 μL, 0.70 mmol) and hexadecane-1-thiol (216 μL, 0.70 mmol) were added in anhydrous dichloromethane (10 mL), the reaction mixture was cooled in an ice bath. Carbon disulfide (43 μL, 0.70 mmol) was then added dropwise, followed by slow addition of triethylamine (108 μL, 0.77 mmol). After a further five minutes, a solution of CBr.sub.4 (466 mg, 1.41 mmol) in dichloromethane was added, followed by stirring at room temperature for two hours. The solution was washed with water (3×10 mL), saturated NaCl solution (2×10 mL) and dried over sodium sulfate. The product was further purified by column chromatography (DCM:PE=1:1) to yield the white solid (161 mg, 56.8%). .sup.1H NMR (400 MHz, Chloroform-d): δ 3.97 (t, J=7.0 Hz, 2H), 3.75 (t, J=6.9 Hz, 2H), 2.86 (t, J=7.4 Hz, 2H), 2.12 (p, J=6.9 Hz, 2H), 2.00 (p, J=6.9 Hz, 2H), 1.66 (p, J=7.5 Hz, 2H), 1.40 (d, J=7.4 Hz, 2H), 1.25 (s, 26H), 0.88 (t, J=6.5 Hz, 3H). .sup.13C NMR (150 MHz, Chloroform-d): δ 193.06, 56.63, 50.52, 38.73, 31.94, 29.70, 29.66, 29.59, 29.50, 29.37, 29.22, 28.65, 28.59, 26.51, 24.20, 22.70, 14.12.

Example 8: Synthesis of Compound 8

[0171] ##STR00020##

[0172] Pyrrolidine (58 μL, 0.70 mmol) and octadecane-1-thiol (238 μL, 0.70 mmol) were added in anhydrous dichloromethane (10 mL), the reaction mixture was cooled in an ice bath. Carbon disulfide (43 μL, 0.70 mmol) was then added dropwise, followed by slow addition of triethylamine (108 μL, 0.77 mmol). After a further five minutes, a solution of CBr.sub.4 (466 mg, 1.41 mmol) in dichloromethane was added, followed by stirring at room temperature for two hours. The solution was washed with water (3×10 mL), saturated NaCl solution (2×10 mL) and dried over sodium sulfate. The product was further purified by column chromatography (DCM:PE=1:1) to yield the white solid (154 mg, 50.9%). .sup.1H NMR (400 MHz, Chloroform-d): δ 3.97 (t, J=7.0 Hz, 2H), 3.75 (t, J=6.9 Hz, 2H), 2.86 (t, J=7.4 Hz, 2H), 2.12 (p, J=6.8 Hz, 2H), 2.00 (p, J=6.9 Hz, 2H), 1.66 (p, J=7.4 Hz, 2H), 1.38 (q, J=7.1 Hz, 2H), 1.25 (s, 28H), 0.88 (t, J=6.6 Hz, 3H). .sup.13C NMR (150 MHz, Chloroform-d): δ 193.06, 56.63, 50.52, 38.73, 31.94, 29.71, 29.67, 29.59, 29.50, 29.37, 29.33, 29.22, 28.65, 28.59, 26.51, 24.20, 22.70, 14.12.

Example 9: Synthesis of Compound 9

[0173] ##STR00021##

[0174] Isoindoline (132 μL, 1.17 mmol) and dodecane-1-thiol (237 mg, 1.17 mmol) were added in anhydrous dichloromethane (10 mL), the reaction mixture was cooled in an ice bath. Carbon disulfide (71 μL, 1.17 mmol) was then added dropwise, followed by slow addition of triethylamine (178 μL, 1.29 mmol). After a further five minutes, a solution of CBr.sub.4 (776 mg, 2.34 mmol) in dichloromethane was added, followed by stirring at room temperature for two hours. The solution was washed with water (3×10 mL), saturated NaCl solution (2×10 mL) and dried over sodium sulfate. The product was further purified by column chromatography (EA:PE=1:25) to yield the white solid (270 mg, 58%). .sup.1H NMR (400 MHz, Chloroform-d) δ 7.38-7.26 (m, 4H), 5.24 (s, 2H), 5.07 (s, 2H), 2.89 (t, J=7.1 Hz, 2H), 1.79-1.63 (m, 2H), 1.40 (s, 2H), 1.25 (s, 16H), 0.88 (t, J=6.2 Hz, 3H). .sup.13C NMR (151 MHz, Chloroform-d) δ 193.52, 134.19, 127.38, 122.11, 61.32, 54.98, 38.05, 31.29, 29.02, 29.01, 28.96, 28.87, 28.72, 28.58, 28.05, 27.95, 22.07, 13.50.

Example 10: Synthesis of Compound 10

[0175] ##STR00022##

[0176] Indoline (130 μL, 1.17 mmol) and dodecane-1-thiol (237 mg, 1.17 mmol) were added in anhydrous dichloromethane (10 mL), the reaction mixture was cooled in an ice bath. Carbon disulfide (71 μL, 1.17 mmol) was then added dropwise, followed by slow addition of triethylamine (178 μL, 1.29 mmol). After a further five minutes, a solution of CBr.sub.4 (776 mg, 2.34 mmol) in dichloromethane was added, followed by stirring at room temperature for two hours. The solution was washed with water (3×20 mL), saturated NaCl solution (10 mL) and dried over sodium sulfate. The product was further purified by column chromatography (EA:PE=1:25) to yield the yellow oil (125 mg, 27%). .sup.1H NMR (400 MHz, Chloroform-d) δ 7.12 (t, J=7.4 Hz, 1H), 7.06 (d, J=6.7 Hz, 1H), 6.91 (d, J=7.6 Hz, 1H), 6.73 (t, J=7.0 Hz, 1H), 3.70 (t, J=8.4 Hz, 2H), 3.01 (t, J=8.2 Hz, 2H), 2.69 (t, J=7.3 Hz, 2H), 1.62-1.54 (m, 2H), 1.38 (s, 2H), 1.25 (s, 16H), 0.88 (s, 3H). .sup.13C NMR (151 MHz, Chloroform-d) δ 151.76, 128.69, 126.84, 123.85, 118.35, 108.67, 56.19, 34.68, 31.32, 29.04, 28.99, 28.92, 28.75, 28.69, 28.33, 28.19, 27.78, 22.09, 13.53.

Example 11: Synthesis of Compound 11

[0177] ##STR00023##

[0178] 2-Oxa-6-azaspiro[3.4]octane (132 mg, 1.17 mmol) and dodecane-1-thiol (237 mg, 1.17 mmol) were added in anhydrous dichloromethane (10 mL), the reaction mixture was cooled in an ice bath. Carbon disulfide (71 μL, 1.17 mmol) was then added dropwise, followed by slow addition of triethylamine (178 μL, 1.29 mmol). After a further five minutes, a solution of CBr.sub.4 (776 mg, 2.34 mmol) in dichloromethane was added, followed by stirring at room temperature for two hours. The solution was washed with water (3×20 mL), saturated NaCl solution (10 mL) and dried over sodium sulfate. The product was further purified by column chromatography (EA:PE=1:3) to yield the white solid (180 mg, 40%). .sup.1H NMR (400 MHz, Chloroform-d) δ 4.43 (ddd, J=19.4, 17.9, 6.1 Hz, 4H), 3.96 (s, 1H), 3.75 (s, 2H), 3.55 (t, J=6.7 Hz, 1H), 2.61 (t, J=6.9 Hz, 2H), 2.19 (t, J=6.8 Hz, 1H), 2.06 (t, J=7.0 Hz, 1H), 1.42 (s, 2H), 1.15 (s, 2H), 1.01 (s, 16H), 0.64 (t, J=6.3 Hz, 3H). .sup.13C NMR (151 MHz, Chloroform-d) δ 193.52, 79.55, 63.48, 57.81, 54.22, 48.50, 45.78, 43.13, 38.04, 35.42, 33.17, 31.17, 29.00, 28.94, 28.85, 28.71, 28.57, 28.03, 27.92, 22.05, 13.49.

Example 12: Synthesis of Compound 12

[0179] ##STR00024##

[0180] Octahydro-1H-isoindole (147 mg, 1.17 mmol) and dodecane-1-thiol (237 mg, 1.17 mmol) were added in anhydrous dichloromethane (10 mL), the reaction mixture was cooled in an ice bath. Carbon disulfide (71 μL, 1.17 mmol) was then added dropwise, followed by slow addition of triethylamine (178 μL, 1.29 mmol). After a further five minutes, a solution of CBr.sub.4 (776 mg, 2.34 mmol) in dichloromethane was added, followed by stirring at room temperature for two hours. The solution was washed with water (3×20 mL), saturated NaCl solution (10 mL) and dried over sodium sulfate. The product was further purified by column chromatography (EA:PE=1:25) to yield the yellow oil (360 mg, 76%). .sup.1H NMR (400 MHz, Chloroform-d) δ 3.66 (dd, J=12.9, 7.4 Hz, 1H), 3.56 (dd, J=13.2, 6.3 Hz, 1H), 3.50-3.39 (m, 1H), 3.32 (dd, J=11.1, 5.7 Hz, 1H), 2.56 (t, J=7.3 Hz, 2H), 2.08 (ddd, J=33.1, 11.8, 5.9 Hz, 2H), 1.36 (dd, J=14.4, 7.5 Hz, 4H), 1.27-1.06 (m, 8H), 0.95 (s, 16H), 0.58 (t, J=6.4 Hz, 3H). .sup.13C NMR (151 MHz, Chloroform-d) δ 193.54, 59.76, 53.96, 38.06, 37.53, 35.14, 31.30, 29.03, 29.01, 28.96, 28.88, 28.73, 28.59, 28.03, 27.95, 25.07, 24.92, 22.07, 21.98, 21.70, 13.51.

Example 13: Synthesis of Compound 13

[0181] ##STR00025##

[0182] 3-Hydroxy pyrrolidine (174 mg, 2 mmol) and dodecane-1-thiol (404 mg, 2 mmol) were added in anhydrous dichloromethane (10 mL), the reaction mixture was cooled in an ice bath. Carbon disulfide (152 mg, 2 mmol) was then added dropwise, followed by slow addition of triethylamine (204 mg, 2.2 mmol). After a further five minutes, a solution of CBr.sub.4 (1326 mg, 4 mmol) in dichloromethane was added, followed by stirring at room temperature for two hours. The solution was washed with water (3×10 mL), saturated NaCl solution (2×10 mL) and dried over sodium sulfate. The product was further purified by column chromatography (DCM:PE=1:6) to yield the white solid (150 mg, 22%). .sup.1H NMR (400 MHz, Chloroform-d) δ 4.60 (s, 1H), 4.25-3.77 (overlap, 4H), 2.85 (t, J=7.1 Hz, 2H), 2.30-1.79 (overlap, 3H), 1.72-1.61 (m, 2H), 1.44-1.35 (m, 2H), 1.25 (s, 16H), 0.88 (t, J=6.3 Hz, 3H). .sup.13C NMR (151 MHz, Chloroform-d) δ 194.12, 71.41, 68.99, 64.58, 54.18, 48.39, 38.73, 31.92, 29.64, 29.59, 29.50, 29.35, 29.22, 28.67, 28.58, 22.69, 14.12.

Example 14: Synthesis of Compound 14

[0183] ##STR00026##

[0184] Piperidine (100 mg, 1.17 mmol) and dodecane-1-thiol (237 mg, 1.17 mmol) were added in anhydrous dichloromethane (10 mL), the reaction mixture was cooled in an ice bath. Carbon disulfide (71 μL, 1.17 mmol) was then added dropwise, followed by slow addition of triethylamine (178 μL, 1.29 mmol). After a further five minutes, a solution of CBr.sub.4 (776 mg, 2.34 mmol) in dichloromethane was added, followed by stirring at room temperature for two hours. The solution was washed with water (3×20 mL), saturated NaCl solution (10 mL) and dried over sodium sulfate. The product was further purified by column chromatography (EA:PE=1:25) to yield the white solid (210 mg, 50%). .sup.1H NMR (400 MHz, Chloroform-d) δ 4.33 (s, 2H), 3.99 (s, 2H), 2.86 (t, J=6.1 Hz, 2H), 1.89-1.58 (m, 8H), 1.40 (s, 2H), 1.27 (s, 16H), 0.89 (s, 3H). .sup.13C NMR (151 MHz, Chloroform-d) δ 195.98, 54.55, 51.21, 38.16, 31.27, 29.00, 28.98, 28.94, 28.85, 28.70, 28.56, 27.94, 25.62, 24.86, 23.55, 22.04, 13.48.

Example 15: Synthesis of Compound 15

[0185] ##STR00027##

[0186] Morpholine (100 mg, 1.17 mmol) and dodecane-1-thiol (237 mg, 1.17 mmol) were added in anhydrous dichloromethane (10 mL), the reaction mixture was cooled in an ice bath. Carbon disulfide (71 μL, 1.17 mmol) was then added dropwise, followed by slow addition of triethylamine (178 μL, 1.29 mmol). After a further five minutes, a solution of CBr.sub.4 (776 mg, 2.34 mmol) in dichloromethane was added, followed by stirring at room temperature for two hours. The solution was washed with water (3×20 mL), saturated NaCl solution (10 mL) and dried over sodium sulfate. The product was further purified by column chromatography (EA:PE=1:25) to yield the white solid (210 mg, 50%). .sup.1H NMR (400 MHz, Chloroform-d) δ 4.36 (s, 2H), 4.07 (s, 2H), 3.79 (s, 4H), 2.86 (t, J=7.2 Hz, 2H), 1.73-1.58 (m, 2H), 1.40 (s, 2H), 1.26 (s, 16H), 0.89 (t, J=6.4 Hz, 3H). .sup.13C NMR (151 MHz, Chloroform-d) δ 197.65, 65.65, 52.62, 50.54, 38.11, 31.27, 29.00, 28.98, 28.93, 28.84, 28.70, 28.55, 27.99, 27.92, 22.04, 13.49.

Example 16: Synthesis of Compound 16

[0187] ##STR00028##

[0188] 4-Methylpiperazine (180 mg, 1.8 mmol) and dodecane-1-thiol (363 mg, 1.8 mmol) were added in anhydrous dichloromethane (10 mL), the reaction mixture was cooled in an ice bath. Carbon disulfide (139 mg, 1.8 mmol) was then added dropwise, followed by slow addition of triethylamine (200 mg, 1.98 mmol). After a further five minutes, a solution of CBr.sub.4 (1200 mg, 3.6 mmol) in dichloromethane was added, followed by stirring at room temperature for two hours. The solution was washed with water (3×10 mL), saturated NaCl solution (2×10 mL) and dried over sodium sulfate. The product was further purified by column chromatography (DCM:PE=1:3) to yield the white solid (270 mg, 40%). .sup.1H NMR (400 MHz, Chloroform-d) δ 4.21 (brs, 4H), 2.85 (t, J=7.2 Hz, 2H), 2.53 (s, 4H), 2.34 (s, 3H), 1.76-1.55 (m, 2H), 1.39 (s, 2H), 1.25 (s, 16H), 0.87 (d, J=6.8 Hz, 3H). .sup.13C NMR (151 MHz, Chloroform-d) δ 197.65, 54.45, 45.62, 38.75, 31.92, 29.65, 29.63, 29.58, 29.49, 29.35, 29.21, 28.60, 28.57, 22.69, 14.13.

Example 17: Synthesis of Compound 17

[0189] ##STR00029##

[0190] Azetidine hydrochloride (187 mg, 2 mmol) and potassium hydroxide (112 mg, 2 mmol) were mixed in THF (10 mL) and stirred for 2 h. The obtained azetidine and dodecane-1-thiol (0.48 mL, 2 mmol) were added in anhydrous dichloromethane (10 mL), the reaction mixture was cooled in an ice bath. Carbon disulfide (0.12 mL, 2 mmol) was then added dropwise, followed by slow addition of triethylamine (0.31 mL, 2.2 mmol). After a further five minutes, a solution of CBr.sub.4 (1300 mg, 4 mmol) in dichloromethane was added, followed by stirring at room temperature for two hours. The solution was washed with water (3×10 mL), saturated NaCl solution (2×10 mL) and dried over sodium sulfate. The product was further purified by column chromatography (DCM:PE=1:8) to yield the pale-yellow solid (270 mg, 40%). .sup.1H NMR (400 MHz, Chloroform-d) δ 4.35 (t, J=7.6 Hz, 4H), 2.83 (t, J=7.5 Hz, 2H), 2.49-2.39 (m, 2H), 1.72-1.62 (m, 2H), 1.38 (brs, 2H), 1.25 (s, 16H), 0.88 (s, 3H). .sup.13C NMR (151 MHz, Chloroform-d) δ 193.88, 56.11, 53.94, 39.10, 31.92, 29.65, 29.58, 29.50, 29.35, 29.20, 28.68, 28.54, 22.69, 15.77, 14.12.

Example 18

[0191] Carbamo(dithioperoxo)thioate analogs alleviate mouse myoblasts (C2C12) atrophy induced by mouse colon cancer cell (C26).

[0192] The diameter measurement method was used to evaluate the diameter of myotubes differentiated from mouse myoblasts (C2C12). The staining method used in the experiment was hematoxylin-eosin staining, referred to as HE staining. The hematoxylin stain is alkaline, positively charged, and easily binds to negatively charged and acidic deoxyribonucleic acid (DNA) in the nucleus with ionic bonding to show blue; while eosin is an acidic dye that dissociates into negatively charged anions in water and easily binds to the positively charged amino groups of proteins in the cytoplasm to show red. The stained cells were placed under a high-magnification microscope to take photos (magnification power: 400), and the diameter of myotubes could be counted using image J software.

[0193] The above method allows to evaluate the effect of the drug on the muscle atrophy cell model. The specific method is as follows.

[0194] C2C12 cells were seeded in 24-well plates in a culture medium of high-glucose DMEM medium containing 10% FBS and 1% P/S, and placed in a 5% CO.sub.2, 37° C. environment. When the cell density reaches 50%˜60%, the culture medium was changed into 2% HS differentiation medium (high-glucose DMEM medium containing 2% HS and 1% P/S); the differentiation medium was changed every 48 h until mature on day 5 or day 6. In addition, C26 cells were inoculated in T75 flasks, and the culture medium was changed into high-glucose DMEM medium containing 10% FBS and 1% P/S, and placed in a 5% CO2, 37° C. environment. While C26 cells (6×10.sup.6 cells/flasks) were passaged, add 20 mL of culture medium to sequentially subculture for 48 h. To obtain the C26 supernatant, centrifuge C26 culture medium at 1000 rpm for 3 min and then at 4000 rpm for 10 min successively. The C26 supermatant and 2% HS differentiation medium were mixed 1:1 (volume ratio) as a muscle atrophy inducing medium. Except for the control group with 2% HS differentiation medium, other each group was added with the equal amounts of muscle atrophy-inducing medium and one group was used as the model group, and the rest groups were used as the experimental groups for drug administration. At the same time, carbamo(dithioperoxo)thioate compounds were added into the cells at the following gradient concentrations.

TABLE-US-00001 TABLE 1 Administration samples for myotubes (C2C12) atrophy assay in example Ser. No. No. Test sample Component 1 CT Control group 2% HS differentiation medium 2 C26 medium Model group 2% HS differentiation medium + C26 medium 3 C26 + 1(25μM) Experimental group 1 2% HS differentiation medium + C26 medium + 25 μM compound 1 4 C26 + 1(50 μM) Experimental group 2 2% HS differentiation medium + C26 medium + 50 μM compound 2 5 C26 + 1(100 μM) Experimental group 3 2% HS differentiation medium + C26 medium + 100 μM compound 3 6 C26 + 2(12.5 μM) Experimental group 4 2% HS differentiation medium + C26 medium + 12.5 μM compound 4 7 C26 + 2(25 μM) Experimental group 5 2% HS differentiation medium + C26 medium + 25 μM compound 5 8 C26 + 2(50 μM) Experimental group 6 2% HS differentiation medium + C26 medium + 50 μM compound 6 9 C26 + 3(25 μM) Experimental group 7 2% HS differentiation medium + C26 medium + 25 μM compound 7 10 C26 + 3(50 μM) Experimental group 8 2% HS differentiation medium + C26 medium + 50 μM compound 8 11 C26 + 3(100 μM) Experimental group 9 2% HS differentiation medium + C26 medium + 100 μM compound 9 12 C26 + 4(3.125 μM) Experimental group 10 2% HS differentiation medium + C26 medium + 3.125 M compound 10 13 C26 + 4(6.25 μM) Experimental group 11 2% HS differentiation medium + C26 medium + 6.25 μM compound 11 14 C26 + 4(12.5 μM) Experimental group 12 2% HS differentiation medium + C26 medium + 12.5 μM compound 12 15 C26 + 5(25 μM) Experimental group 13 2% HS differentiation medium + C26 medium + 25 μM compound 13 16 C26 + 5(50 μM) Experimental group 14 2% HS differentiation medium + C26 medium + 50 μM compound 14 17 C26 + 6(25 μM) Experimental group 15 2% HS differentiation medium + C26 medium + 25 μM compound 15 18 C26 + 6(50μM) Experimental group 16 2% HS differentiation medium + C26 medium + 50 μM compound 16 19 C26 + 6(100 μM) Experimental group 17 2% HS differentiation medium + C26 medium + 100 μM compound 17 20 C26 + 7(25 μM) Experimental group 18 2% HS differentiation medium + C26 medium + 25 μM compound 18 21 C26 + 7(50 μM) Experimental group 19 2% HS differentiation medium + C26 medium + 50 μM compound 19 22 C26 + 7(100 μM) Experimental group 20 2% HS differentiation medium + C26 medium + 100 μM compound 20 23 C26 + 8(25 μM) Experimental group 21 2% HS differentiation medium + C26 medium + 25 μM compound 21 24 C26 + 8(50 μM) Experimental group 22 2% HS differentiation medium + C26 medium + 50 μM compound 22 25 C26 + 8(100 μM) Experimental group 23 2% HS differentiation medium + C26 medium + 100 μM compound 23 26 C26 + 9(25 μM) Experimental group 24 2% HS differentiation medium + C26 medium + 25 μM compound 24 27 C26 + 9(50 μM) Experimental group 25 2% HS differentiation medium + C26 medium + 50 μM compound 25 28 C26 + 9(100 μM) Experimental group 26 2% HS differentiation medium + C26 medium + 100 μM compound 26 29 C26 + 10(25 μM) Experimental group 27 2% HS differentiation medium + C26 medium + 25 μM compound 27 30 C26 + 10(50 μM) Experimental group 28 2% HS differentiation medium + C26 medium + 50 μM compound 28 31 C26 + 10(100 μM) Experimental group 29 2% HS differentiation medium + C26 medium + 100 μM compound 29 32 C26 + 11(25 μM) Experimental group 30 2% HS differentiation medium + C26 medium + 25 μM compound 30 33 C26 + 11(50 μM) Experimental group 31 2% HS differentiation medium + C26 medium + 50 μM compound 31 34 C26 + 12(25 μM) Experimental group 32 2% HS differentiation medium + C26 medium + 25 μM compound 32 35 C26 + 12(50 μM) Experimental group 33 2% HS differentiation medium + C26 medium + 50 μM compound 33 36 C26 + 12(100 μM) Experimental group 34 2% HS differentiation medium + C26 medium + 100 μM compound 34 37 C26 + 13(25 μM) Experimental group 35 2% HS differentiation medium + C26 medium + 25 μM compound 35 38 C26 + 13(50 μM) Experimental group 36 2% HS differentiation medium + C26 medium + 50 μM compound 36 39 C26 + 14(25 μM) Experimental group 37 2% HS differentiation medium + C26 medium + 25 μM compound 37 40 C26 + 14(50 μM) Experimental group 38 2% HS differentiation medium + C26 medium + 50 μM compound 38 41 C26 + 15(25 μM) Experimental group 39 2% HS differentiation medium + C26 medium + 25 μM compound 39 42 C26 + 15(50 μM) Experimental group 40 2% HS differentiation medium + C26 medium + 50 μM compound 40 43 C26 + 16(25 μM) Experimental group 41 2% HS differentiation medium + C26 medium + 25 μM compound 41 44 C26 + 16(50 μM) Experimental group 42 2% HS differentiation medium + C26 medium + 50 μM compound 42 45 C26 + 17(25 μM) Experimental group 43 2% HS differentiation medium + C26 medium + 25 μM compound 43 46 C26 + 17(50 μM) Experimental group 44 2% HS differentiation medium + C26 medium + 50 μM compound 44

[0195] Wherein, the serial numbers correspond to the numbers of the accompanying figures, that is, FIG. 1-46 correspond to the samples of serial numbers 1-46 in Table 1. μM refers to μmol/L.

[0196] Myotube diameter was measured as follows.

[0197] After 48 h of action, the myotubes were fixed with fixative solution (anhydrous ethanol:formaldehyde:glacial acetic acid volume ratio=20:2:1) for more than 1 h, stained using hematoxylin-eosin staining method, and placed under a high-magnification microscope to acquire images and counted the diameter of myotubes using image J. The muscle atrophy reversal rate was calculated according to the following equation.

Muscle atrophy reversal rate=(Average value of myotubes in drug administration group−Average value of myotubes in model group)/(Average value of myotubes in control group−Average value of myotubes in model group)×100%

Results and Conclusions

[0198] Appendix FIGS. 1-46 are representative images of HE staining of carbamo(dithioperoxo) thioate analogues alleviating C2C12 mature myotubes atrophy induced by C26 cell culture medium, and the appendix Table 2 is a table of myotube statistical results. As shown in FIGS. 1-46 and Table 2, carbamo(dithioperoxo)thioate analogs showed a significant reversal of myotube atrophy in a concentration-dependent manner. From the results, it can be found that the long-chain substituted carbamo(dithioperoxo)thioate basically have better reversal of myotube atrophy, but their activities are closely correlated with the chain length. Among them, compound 4 has the most significant effect with 92.83% reversal of myotube atrophy at a non-cytotoxic 12.5 μM. This compound serves as a candidate for further research and development. However, the activity was lower when the chain length was 18 carbon atoms (compound 8).

TABLE-US-00002 TABLE 2 Statistical results table of myotubes Myotube atrophy reversal rate ( % ) Compound No. 25 μM 50 μM l00 μM Compound 1 18.39% 2.51% 36.26% Compound 2 16.94% 43.90% (25 μM) 61.05% (50 μM) (12.5 μM) Compound 3 35.76% 33.40% 46.11% Compound 4 37.78% 54.53% 92.83% (3.125 μM) (6.25 μM) (12.5 μM) Compound 5 23.27% 40.28% Compound 6 20.41% 35.98% 33.80% Compound 7 41.05% 28.79% 43.99% Compound 8 −1.83% 17.41%  6.10% Compound 9 12.22% 29.24% 60.06% Compound 10 10.82% 25.32% 45.93% Compound 11 42.30% 64.65% Compound 12 20.85% 49.43% 66.73% Compound 13 18.05% 42.38% Compound 14 17.02% 43.19% Compound 15 26.47% 48.24% Compound 16 31.39% 46.75% Compound 17 26.34% 53.97%

Example 19

[0199] Experimental results of compound 4 alleviating 3T3-L1 adipocytes lipolysis.

[0200] Glycerol assay was used to evaluate intracellular lipid content. Glycerol kinase phosphorylates glycerol to glycerol 3-phosphate; glycerol 3-phosphate is oxidized by glycerophosphate oxidase to produce hydrogen peroxide; the chromogenic substrate is converted to benzoquinone imine in the presence of peroxidase, and its optical density value is proportional to the glycerol concentration.

[0201] The above methods allow to evaluate the effect of drugs on the fat lipolysis cell model. The methods are as follows:

[0202] 3T3-L1 cells were seeded in 6-well plates in a culture medium (high-glucose DMEM medium containing 10% FBS and 1% P/S) and placed in a 5% CO.sub.2, 37° C. environment. The cells were allowed to grow to 100% confluence and continued to fuse for 3 days to start the differentiation operation. The culture medium for the first differentiation was high-glucose DMEM medium containing 0.5 mM IBMX, 5 mg/mL insulin, 1 μM dexamethasone and 10% FBS and 1% P/S, and then differentiated 3T3-L1 adipocytes for 72 h; The culture medium for the second differentiation was high-glucose DMEM medium containing 5 mg/mL insulin and 10% FBS, and 1% P/S, and then differentiated 3T3-L1 adipocytes for 72 h; the culture medium for the third differentiation was high-glucose DMEM medium containing 10% FBS, and 1% P/S, and then differentiated 3T3-L1 for 72 h; After successful differentiation, it was obvious that there were a large number of oil droplets in the cells. In addition, C26 cells were inoculated in T75 flasks in the culture medium (high-glucose DMEM medium containing 10% FBS, and 1% P/S) and placed in a 5% CO.sub.2, 37° C. environment. While C26 cells (6×10.sup.6 cells/flask) were passaged, add 15 mL of phenol red-free high-glucose DMEM culture medium to the T75 flask with 100% confluent C26 cells and sequentially subculture for 48 h. To obtain the supernatant, centrifuge C26 culture medium at 1000 rpm for 3 min and at 4000 rpm for 10 min successively, and take the supernatant to obtain the C26 supernatant successively. The C26 supernatant was mixed with phenol red-free high-glucose DMEM medium at 1:1 ratio as a fat lipolysis-inducing medium. Except for the control group with phenol red-free high-glucose DMEM medium, the other each group was added with the same amount of fat lipolysis-inducing liquid; one group was used as the model group, and the rest groups were used as the experimental groups for drug administration. At the same time, compound 4 stock solution was also added into the cells at the following concentrations of 12.5 μM, 25 μM, 50 μM, 100 μM.

TABLE-US-00003 TABLE 3 Administration samples for adipocyte lipolysis in Example 19 Ser. No. No. Test sample component 1 CT (Control) Control group Phenol red free- high glucose DMEM culture medium 2 C26 medium Model group Phenol red free- high glucose DMEM culture medium + C26 medium 3 C26 + 4 (12.5 μM) Experimental group 1 Phenol red free- high glucose DMEM culture medium + C26 medium + 12.5 μM compound 4 4 C26 + 4(25 μM) Experimental group 2 Phenol red free- high glucose DMEM culture medium + C26 medium + 25 μM compound 4 5 C26 + 4(50 μM) Experimental group 3 Phenol red free- high glucose DMEM culture medium + C26 medium + 50 μM compound 4 6 C26 + 4(100M) Experimental group 4 Phenol red free- high glucose DMEM culture medium + C26 medium + 100 μM compound 4

[0203] The glycerol detection method was performed as follows: after 48 h of action, the glycerol content in the supernatant was detected using the glycerol detection kit from Beijing Applygen Gene Technology Co., Ltd.

[0204] Results and Conclusions: Refer to the attached FIG. 47.

[0205] The attached FIG. 47 shows the glycerol detection result of compound 4. As shown in FIG. 47, compound 4 showed a concentration-dependent reduction of glycerol released from 3T3-L1 mature adipocytes induced by C26 cell culture medium. The cellular glycerol contents of the control group, model group, experimental group 1, experimental group 2, experimental group 3 and experimental group 4 were 287.44 μM, 441.95 μM, 379.44 μM, 347.14 μM, 313.67 μM and 310.95 μM, respectively.

Example 20

[0206] The experimental results of cancer cachexia animal models treated with compound 4, by the following methods.

[0207] C26 cells were cultured in T75 culture flasks in the culture medium (RPMI-1640 medium containing 10% FBS, and P/S) and placed in a 5% CO.sub.2, 37° C. environment. The cells were harvested by centrifugation at 1000 rpm for 3 min, and washed with ice-cold PBS buffer to remove the remaining culture medium and prepared into a cell suspension of 1×10.sup.7 cells/mL. The cell suspension was inoculated into the left and right armpits of BALB/c mice with 1×10.sup.6 cells/mouse for subsequent inoculation. When the tumor volume increased to about 800 cm3, the tumor was removed and homogenized at 3.5 mL of ice-old saline/g to obtain tumor tissue suspension. The mice to be inoculated were grouped according to their body weight, and the cell suspension was inoculated into the left armpit of BALB/c mice at the amount of 100 μL/mouse. The administration of the drug was started the day after inoculation. Compound 4 was first dissolved in DMSO and then mixed with pre-warmed PBS solution (37° C.) to form a homogeneous and stable solution at a final concentration of 1 mg/mL (3% DMSO+2% anhydrous ethanol+1% polyoxyethylene castor oil). The dose was 5 mg/kg and the route of administration was oral gavage (i.g). The body weight, body temperature, tumor size and food intake of the mice were monitored daily. The mice in the model group were considered to be in the advanced stage of cachexia when they were about 10% weight loss after 16 days. The muscle grip of mice's limbs was measured, and samples of gastrocnemius muscle, epididymal fat and tumor were obtained after the mice were executed by decolonization and the tissue samples were weighed.

[0208] The measurement method of the muscle grasping force is as follows: The researcher holds the mouse steadily with his right hand, puts the mouse on the “YLS-13A rat and mouse grasping force measuring instrument” to let the forelimbs of mouse firmly grasp the grasping plate and uses his left hand to stabilize the grasping plate. To measure the muscle grasping force of the mouse, the researcher slowly releases his left hand from the grasping plate and immediately uses his right hand to pull the mouse's tail backward slowly until the forelimbs are free from the grasping plate. Each mouse is repeated 8 times, and the average value of the 8 times is used as the skeletal muscle strength index of each mouse.

[0209] Results and Conclusions: Referring to FIGS. 48 to 58, the three curves in the figures represent the healthy group, the C26 tumor model group and the dosing group (compound 4 group, where compound 4 was administrated at a dose of 5 mg/kg), respectively.

[0210] The attached FIGS. 48 to 51 show the body weight with tumors (FIG. 48), the body weight without tumors (FIG. 49), the tumor volume (FIG. 50) and the real tumor photos (FIG. 51) during the survival period of the mice, in which the body weight with tumors and the body weight without tumors are the average weight of 8 mice, and the tumor volume is the average volume of the tumors of 8 mice, and the real tumor photos are the real photos of the tumors of 8 mice. As shown in FIG. 48, the body weight of mice in the healthy group continued to increase, while the body weight of the tumor-bearing mice in the C26 tumor model group stated to decrease from the beginning to the 11th day of the experiment, and continued to decrease until the end of the experiment. As shown in attached FIG. 49, the same was true for the body weight without tumors, while the compound 4 group can significantly alleviate the weight loss of the mice and by the end of the experiment, both the body weight with tumor and the body weight without tumor were higher than those in the C26 tumor model group, and the difference was statistically significant (p<0.01). However, as shown in FIGS. 50 and 51, the tumor volume was slightly reduced in the compound 4 group compared with the C26 tumor model group, but the difference was not significant, indicating that the compound 4 had no significant inhibitory effect on growth of C26 tumors.

[0211] The average daily food intake and the average accumulative food intake during the survival period of mice are shown in FIG. 52 to 53, which are the average calculation results of 8 mice. The mice in the C26 tumor model group showed significant decrease in food intake compared to the healthy group. The compound 4 group showed higher food intake than the C26 tumor model group, suggesting that it improved appetite.

[0212] The attached FIGS. 54 to 55 show the mass of the gastrocnemius muscle in mice and the real pictures of the gastrocnemius muscle, and the gastrocnemius muscle mass is the average value of 8 mice, and the real pictures of the gastrocnemius muscle is the result of 8 mice/group. As shown in FIGS. 54 and 55, the gastrocnemius muscle mass of mice in the C26 tumor model group was significantly lighter than that in the healthy group, and the difference was statistically significant (p<0.001). Compound 4 could significantly alleviate gastrocnemius muscle atrophy (p<0.05). FIG. 56 shows the muscle grasping force of the mice's limbs. The muscle grasping force of the mice in the C26 tumor model group was significantly lower than that of the healthy group and the compound 4 group, and the difference was statistically significant (p<0.001). Compound 4 could significantly enhance the muscle grasping force (p<0.05).

[0213] The attached FIGS. 57 to 58 show the epididymal fat mass of mice with real pictures of epididymal fat. As shown in the figure, the epididymal fat mass of mice in the C26 tumor model group was significantly lighter than that in the healthy group and compound 4 group, and the difference was statistically significant (p<0.01). Compound 4 could significantly increase the epididymal fat mass (p<0.05).

[0214] The above results suggest that compound 4 could alleviate the weight loss, muscle atrophy, fat degradation and body temperature decrease caused by cancer cachexia and improve appetite without affecting the tumor size.

[0215] The above described is a preferred embodiment of the present invention and it should be noted that, for those researchers of ordinary skill in the technical field covered by the present invention, several supplements and improvements can be made without departing from the method of the present invention, and these supplements and improvements should also be considered as the protection scope of the present invention.